NCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02773030 2024-06-25
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn